Arterial Remodelling Technologies announced that it has signed a structured buyout agreement with Terumo Corporation. Under the agreement, Arterial Remodelling Technologies and Terumo Corporation will collaborate in the development of a drug-eluting bioresorbable scaffold or stent, intended for use in the treatment of coronary artery disease.
Arterial Remodelling Technologies Security Holders will retain full ownership of the Arterial Remodelling Technologies bioresorbable scaffold technology for all other indications. Terumo Corporation will make staged R&D investments in Arterial Remodelling Technologies and Arterial Remodelling Technologies has granted an exclusive option to Terumo Corporation to purchase Arterial Remodelling Technologies at any time prior to the initiation of clinical trials.
Arterial Remodelling Technologies’ advanced bioresorbable scaffold is designed to provide a transient effective scaffold that dismantles and relinquishes its primary mechanical scaffolding function after three months, which is commonly recognised by experts as the requisite length of time necessary to allow the healing process to stabilise the artery following trauma generated by angioplasty, and to avoid recoil and constrictive remodelling.
